Evaluation of Iluvien for the treatment of DME

Registry ID

EUCTR2016-001680-37

Source registry

EUCTR

Status

Ongoing

Phase

PHASE4

Sponsor

Dr. José Maria Ruiz Moreno

Start date

2016-10-22

Last update

2026-08-16

Conditions

• Diabetic Macular Edema

Summary

To assess the efficacy of ILUVIEN in terms of change in best corrected visual acuity (BCVA) in patients with DME insufficiently responsive to prior available therapies with or without prior history of intraocular corticosteroid therapy.

Locations

• , , Spain

Related clinical trials

• A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
• COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
• CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
• Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
• A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
• A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

View on source registry